Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson’s Disease

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F24%3A10158847" target="_blank" >RIV/00098892:_____/24:10158847 - isvavai.cz</a>

Alternative codes found

RIV/00159816:_____/24:00081261 RIV/00216224:14110/24:00138483 RIV/00216208:11110/24:10488975 RIV/61989592:15110/24:73626859 RIV/00064165:_____/24:10488975

Result on the web

<a href="https://journals.viamedica.pl/neurologia_neurochirurgia_polska/article/view/100132" target="_blank" >https://journals.viamedica.pl/neurologia_neurochirurgia_polska/article/view/100132</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5603/pjnns.100132" target="_blank" >10.5603/pjnns.100132</a>

Result language

angličtina

Original language name

Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson’s Disease

Original language description

Aim of study: To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG. Clinical rationale for study: Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson’s Disease (PD). Polyneuropathy is a well-known complication of PD treatment. Patients treated with oral levodopa usually suffer from subclinical or mild chronic sensory polyneuropathy. However, severe acute polyneuropathy occurs in patients treated with LCIG, which is causally related to the treatment and leads to its immediate discontinuation. The etiology is not yet clear, but some patients with acute polyneuropathy have been given high doses of LCIG. Material and methods: A retrospective multicentre study of patients treated with LCIG was performed. Patients with acute polyneuropathy were subjected to a detailed analysis including statistical processing. Results: Of 183 patients treated with LCIG in seven centres, six patients (five females, median age 63 years) developed acute polyneuropathy with LCIG discontinuation. The median (interquartile range) initial and final LE daily dose in patients with and without acute polyneuropathy was 3,015 (2,695–3,184) and 1,898 (1,484–2,167) mg, respectively. The final LE daily dose of 2,605 mg cut-off had 83% sensitivity and 93% specificity for the prediction of acute polyneuropathy. Conclusions and clinical implications: The risk of acute polyneuropathy in LCIG-treated patients was associated with a daily LE dose of greater than 2,605 mg or with more than a 62% increase in the daily LE dose during LCIG treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

<a href="/en/project/LX22NPO5107" target="_blank" >LX22NPO5107: National institute for Neurological Research</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neurologia i Neurochirurgia Polska

ISSN

0028-3843

e-ISSN

1897-4260

Volume of the periodical

58

Issue of the periodical within the volume

6

Country of publishing house

PL - POLAND

Number of pages

7

Pages from-to

586-592

UT code for WoS article

001360325600001

EID of the result in the Scopus database

2-s2.0-85213726825